Published online February 15, 2005
PEDIATRICS Vol. 115 No. 3 March 2005, pp. e344-e355 (doi:10.1542/peds.2004-1678)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ries, M.
Right arrow Articles by Schiffmann, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ries, M.
Right arrow Articles by Schiffmann, R.
Related Collections
Right arrow Nutrition & Metabolism

ELECTRONIC ARTICLE

Pediatric Fabry Disease

Markus Ries, MD*, Surya Gupta, MD{ddagger}, David F. Moore, MD, PhD, DIC§, Vandana Sachdev, MD||, Jane M. Quirk, MS*, Gary J. Murray, PhD*, Douglas R. Rosing, MD||, Chevalia Robinson, RN, BSN*, Ellen Schaefer, MD, Andreas Gal, MD, PhD, James M. Dambrosia, PhD#, Scott C. Garman, PhD**, Roscoe O. Brady, MD* and Raphael Schiffmann, MD*

* Developmental and Metabolic Neurology Branch
# Biostatistics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland
{ddagger} Department of Pediatrics, Temple University Children's Medical Center, Philadelphia, Pennsylvania
§ Section of Neurology, Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
|| Cardiovascular Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
Institute of Human Genetics, University Hospital Eppendorf, University of Hamburg, Hamburg, Germany
** Department of Biochemistry and Molecular Biology, University of Massachusetts, Amherst, Massachusetts

Background. Fabry disease is an underdiagnosed, treatable, X-linked, multisystem disorder.

Objectives. To test the hypothesis that quality of life and sweating are decreased among pediatric patients with Fabry disease, compared with control subjects, and to provide quantitative natural history data and novel clinical end points for therapeutic trials.

Design. Prospective, cross-sectional, observational study.

Setting. Referral to the National Institutes of Health.

Participants. Twenty-five male children with Fabry disease (mean age: 12.3 ± 3.5 years) and 21 age-matched control subjects.

Main Outcome Measures. Quality of life (measured with the Child Health Questionnaire) and sweating (assessed with the quantitative sudomotor axon reflex test).

Results. Quality of life scores for pediatric patients <10 years of age with Fabry disease, compared with published normative values, were 55 ± 17 vs 83 ± 19 for bodily pain and 62 ± 19 vs 80 ± 13 for mental health. Bodily pain scores for patients ≥10 years of age were 54 ± 22 vs 74 ± 23. Sweat volume in the Fabry disease group was 0.41 ± 0.46 µL/mm2, compared with 0.65 ± 0.44 µL/mm2 in the control group. Renal function, urinary protein excretion, and cardiac function and structure were normal for the majority of patients. The 3 patients with residual {alpha}-galactosidase A activity ≥1.5% of normal values were free of cornea verticillata and had normal serum and urinary globotriaosylceramide levels. All other children had glycolipid levels comparable to those of adult patients with Fabry disease. Acroparesthesia and cardiac abnormalities were generally present before anhidrosis and proteinuria. Mapping of the missense mutations on the crystallographic structure of {alpha}-galactosidase A revealed that the mutations were partially surface-exposed and distal to the active site among individuals with residual enzyme activity. Mutations associated with left ventricular hypertrophy (defined as left ventricular mass index of >51 g/m2.7) were localized near the catalytic site of the enzyme.

Conclusions. Despite the absence of major organ dysfunction, Fabry disease demonstrates significant morbidity already in childhood. We have identified important, potentially correctable or preventable, outcome measures for future therapeutic trials. Prevention of complications involving major organs should be the goal for long-term specific therapy.

Key Words: adolescence • child • human • Fabry disease • genetics • cornea verticillata • pain • acroparesthesia • diarrhea • heart • cardiomyopathy • echocardiogram • kidney • proteinuria • {alpha}-galactosidase A • quantitative sudomotor axon reflex test • sweating • quality of life

Abbreviations: GFR, glomerular filtration rate • LVH, left ventricular hypertrophy • LV, left ventricle • GALA, {alpha}-galactosidase A • Gb3, globotriaosylceramide • RWT, relative wall thickness • QSART, quantitative sudomotor axon reflex test • CI, confidence interval • LVM, left ventricular mass

Accepted Oct 14, 2004.




This article has been cited by other articles:


Home page
 NDT PlusHome page
F. Barbey, O. Lidove, and A. Schwarting
Fabry nephropathy: 5 years of enzyme replacement therapy--a short review
NDT Plus, February 1, 2008; 1(1): 11 - 19.
[Full Text] [PDF]

Home page
 J Clin PharmacolHome page
M. Ries, J. T. Clarke, C. Whybra, A. Mehta, K. S. Loveday, R. O. Brady, M. Beck, and R. Schiffmann
Enzyme Replacement in Fabry Disease: Pharmacokinetics and Pharmacodynamics of Agalsidase Alfa in Children and Adolescents
J. Clin. Pharmacol., October 1, 2007; 47(10): 1222 - 1230.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
G. M. Pastores, E. Boyd, K. Crandall, A. Whelan, L. Piersall, and N. Barnett
Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease
Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1920 - 1925.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
R. Schiffmann, H. Askari, M. Timmons, C. Robinson, W. Benko, R. O. Brady, and M. Ries
Weekly Enzyme Replacement Therapy May Slow Decline of Renal Function in Patients with Fabry Disease Who Are on Long-Term Biweekly Dosing
J. Am. Soc. Nephrol., May 1, 2007; 18(5): 1576 - 1583.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. F. Moore, O. V. Krokhin, R. C. Beavis, M. Ries, C. Robinson, E. Goldin, R. O. Brady, J. A. Wilkins, and R. Schiffmann
Proteomics of specific treatment-related alterations in Fabry disease: A strategy to identify biological abnormalities
PNAS, February 20, 2007; 104(8): 2873 - 2878.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
M. Ries, H. J. Kim, C. K. Zalewski, M. A. Mastroianni, D. F. Moore, R. O. Brady, J. M. Dambrosia, R. Schiffmann, and C. C. Brewer
Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease
Brain, January 1, 2007; 130(1): 143 - 150.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
R. Schiffmann, M. Ries, M. Timmons, J. T. Flaherty, and R. O. Brady
Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting
Nephrol. Dial. Transplant., February 1, 2006; 21(2): 345 - 354.
[Abstract] [Full Text] [PDF]

Home page
 AAP NewsHome page
R. Hopkin
Treatments now available for lysosomal storage diseases
AAP News, July 1, 2005; 26(7): 10 - 11.
[Full Text]

Home page
 Arch DermatolHome page
M. Ries and R. Schiffmann
Fabry Disease: Angiokeratoma, Biomarker, and the Effect of Enzyme Replacement Therapy on Kidney Function
Arch Dermatol, July 1, 2005; 141(7): 904 - 905.
[Full Text] [PDF]